FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors [0.03%]
儿科脑肿瘤中的FGFR异常及FGFR抑制剂的潜在作用
Sameer Farouk Sait,Tejus Bale,Matthias A Karajannis
Sameer Farouk Sait
A wide spectrum of genomic events leading to dysregulated fibroblast growth factor receptor (FGFR) signaling have been reported across low-grade and high-grade glial/glioneuronal tumors. These events include structural alterations, such as ...
Enabling precision medicine and targeted therapeutics in low- and middle-income country [0.03%]
在中低收入国家开展精准医疗和靶向治疗
Nisreen Amayiri,Girish Chinnaswamy
Nisreen Amayiri
Childhood brain tumors are the leading cause of cancer-related morbidity and mortality in children worldwide. Delayed diagnosis and inadequate diagnostic and treatment infrastructure are significant barriers to an optimal outcome in low- an...
A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma [0.03%]
尼拉帕利联合肿瘤治疗电场治疗复发性4级胶质瘤的II期临床研究
Elizabeth C Cordell,Maikel Mansour,Austin R Pantel et al.
Elizabeth C Cordell et al.
Background: In preclinical models, tumor treating fields (TTFields) therapy promotes homologous repair deficiency (HRD), inducing potential sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The aim of this st...
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort [0.03%]
Belzutifan(LITESPARK-001)Ⅰ期研究：胶质母细胞瘤扩展队列的疗效和安全性总结报告
Roy E Strowd,Macarena de la Fuente,Todd M Bauer et al.
Roy E Strowd et al.
Recurrent isocitrate dehydrogenase (IDH) wild-type glioblastoma has no established standard-of-care treatment. Preclinical models have demonstrated that hypoxia-inducible factor-2 alpha (HIF-2α) contributes to stabilizing the hypoxic envir...
Elena Pasquinelli,Milena Guidi,Iacopo Sardi
Elena Pasquinelli
Pineal region tumors are rare and biologically heterogeneous central nervous system neoplasms that occur predominantly in the pediatric population and are associated with significant morbidity and mortality. Among these, pineal parenchymal ...
"It was complete chaos day and night and no one was able to help": A qualitative study on the support needs of family members exposed to violence by patients with brain tumors [0.03%]
“日夜混乱无人可寻助”——关于暴力行为被害者家属的需求的定性研究：施暴者为脑肿瘤患者
Amina Guenna Holmgren,Annika Malmström,Eskil Degsell et al.
Amina Guenna Holmgren et al.
Background: This study is part of the Swedish national research project BRAVE ( B rain Tumor R elated A ggression and V iolence E xposure), which has highlighted extensive suffering among family members exposed to violenc...
Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab [0.03%]
替莫唑胺耐药的IDH突变型胶质瘤贝伐单抗治疗失败的临床及影像学预后因素分析
Collin T Le,Francesco Sanvito,Chuyin Yang et al.
Collin T Le et al.
Background: While bevacizumab, an anti-angiogenic monoclonal antibody, is approved for recurrent IDH wild-type glioblastoma, reports on clinical outcomes of IDH-mutant gliomas receiving this therapy are scarce. We retrosp...
Rapid and profound radiological and plasma ctDNA responses to dabrafenib plus trametinib in BRAF-mutant papillary craniopharyngioma [0.03%]
达拉菲尼联合曲美替尼治疗BRAF突变型乳头状颅咽管瘤的快速而显著的放射学和血浆ctDNA反应
Santiago Cabezas-Camarero,Rebeca Pérez-Alfayate,Vanesa García-Barberán et al.
Santiago Cabezas-Camarero et al.
A 38-year-old male patient was diagnosed with a BRAF-V600E mutant papillary craniopharyngioma. Due to the neurological and endocrine sequalae from multiple surgeries, irradiation of residual tumor was disregarded. Dabrafenib plus trametinib...
Utility of dynamic 18F-fluoroethyl-L-tyrosine positron emission tomography in determining pseudoprogression from tumor recurrence in the 6 months following radiation therapy for glioblastoma [0.03%]
动态18F-氟乙基-L-酪氨酸正电子发射断层扫描在放射治疗后6个月内区分胶质母细胞瘤假进展和肿瘤复发中的作用
Kevin Jang,Patrick Horsley,Dale Bailey et al.
Kevin Jang et al.
Background: Distinguishing early recurrence from pseudoprogression after chemoradiotherapy remains a major challenge in glioblastoma. Although 18-F-fluroethyl-L-tyrosine (FET)-PET is increasingly used, reliance on static ...
Impact of Bevacizumab treatment intervals on surgical interventions in pediatric neuro-oncology [0.03%]
贝伐单抗不同给药间隔对儿童神经肿瘤外科手术干预的影响
Hannah Schned,Maria Aliotti Lippolis,Cora Hedrich et al.
Hannah Schned et al.
Background: Bevacizumab (BVZ) is widely used in patients with central nervous system (CNS) tumors. Due to its potential to impair wound healing, a minimum interval of 28 days between BVZ administration and surgery - both ...